Germany Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Germany Next-Generation Sequencing (NGS) Services Market was valued at $111.1 Million in 2017 and projected to reach to $290.7 Million by 2022, representing a compound annual growth rate of 21.2%. Germany's NGS services market is positioned for sustained growth through 2022 and beyond, driven by increasing healthcare investments, growing demand for personalized medicine, and expanding clinical applications of genomic sequencing.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Germany Next-Generation Sequencing (NGS) Services Market Trends and Insights
- This expansion reflects Germany's position as a leading European hub for genomic research and precision medicine adoption.
- Germany's strong healthcare infrastructure, coupled with significant investment in biotechnology and genomic research initiatives, has positioned the country as a key driver of NGS service demand across Europe. The 21.2% compound annual growth rate (CAGR) observed in Germany outpaces global trends, underscoring the nation's commitment to advancing personalized medicine and diagnostic capabilities.
- Germany's pharmaceutical and diagnostic sectors have increasingly integrated NGS technologies into clinical workflows, supporting cancer genomics, rare disease diagnosis, and pharmacogenomics applications.
- The market's trajectory from 2017 to 2022 reflects Germany's regulatory support for genomic medicine and the growing adoption of NGS services among hospitals, research institutions, and private diagnostic laboratories throughout the country..
Key Market Statistics
- CAGR (2017-2022) 21.2% CAGR
- Market Size, 2017 ~USD 111.1 Million
- Forecast, 2022 ~USD 290.7 Million
- Country Germany
Germany Next-Generation Sequencing (NGS) Services Market Overview
Rapid Market Expansion :
Germany's NGS services market grew from $111.1 million in 2017 to $290.7 million by 2022, representing a 21.2% CAGR and demonstrating strong adoption of genomic sequencing technologies across the country.
European Research Leadership :
Germany maintains a prominent position as a leading European hub for genomic research and precision medicine, supported by world-class research institutions and pharmaceutical companies investing heavily in NGS capabilities.
Healthcare Infrastructure Advantage :
Germany's robust healthcare system and regulatory framework provide a stable foundation for NGS service expansion, enabling seamless integration of advanced sequencing technologies into clinical diagnostics and research workflows.
Precision Medicine Adoption :
Increasing adoption of precision medicine approaches in German healthcare facilities drives demand for NGS services, particularly in oncology, rare disease diagnosis, and personalized treatment planning.
Germany Next-Generation Sequencing (NGS) Services Market Dynamics
- The country's strong pharmaceutical and biotechnology sectors continue to fuel innovation and service adoption across academic institutions, hospitals, and private diagnostic laboratories. Future growth will be supported by declining sequencing costs, regulatory harmonization within the EU, and rising awareness of genomic medicine among healthcare providers and patients.
- Germany's commitment to precision medicine initiatives and genomic research funding ensures continued market expansion and technological advancement in NGS service delivery..
Market Ecosystem
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The next-generation sequencing services market, valued at US$3.40 billion in 2024, stood at US$3.80 billion in 2025 and is projected to advance at a resilient CAGR of 18.2% from 2025 to 2030, culminating in a forecasted valuation of US$8.77 billion by the end of the period. The global next-generation sequencing services market is growing as sequencing is used more widely in oncology, rare disease diagnostics, infectious disease monitoring, and broader precision medicine initiatives, with healthcare providers and biopharmaceutical companies increasingly outsourcing complex genomic workflows to specialized service partners.
KEY TAKEAWAYS
-
By RegionThe North American next-generation sequencing services market accounted for a 40.8% revenue share in 2024.
-
By OfferingsBy offering, the products segment dominated the next-generation sequencing services market in 2024.
-
By Service typeBy type, the services segment is expected to register the highest CAGR of 18.0%.
-
By End userIn the next-generation sequencing services end user market, the academic & research institutes segment is projected to grow at the fastest rate from 2025 to 2030.
-
By ApplicationBy application, the diagnostics segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeIllumina, Inc., Thermo Fisher Scientific, and Eurofins Scientific were identified as some of the star players in the North American next-generation sequencing services market, given their strong market share and product footprint.
-
Competitive LandscapeNovogene, Co. Ltd., MedGenome, and Singular Genomics, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The global next-generation sequencing services market continues to grow significantly as a larger number of organizations decide to use sequencing services outside their own facilities to obtain quality genomic data. There is an increasing need for services that facilitate the earlier and more accurate detection of diseases, the selection of appropriate therapies, and the application of translational research, both in clinical and research domains. The speed of the cancer-related application (tumor profiling, MRD, liquid biopsy) usage, as well as rare and inherited diseases testing, reproductive health screening, and infectious disease surveillance, is going up.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders of the next-generation sequencing services market is evolving in line with shifting healthcare priorities, rapid advancements in sequencing technologies and analytics, and increasing demand for personalized, data-rich care worldwide. Hospitals and clinical labs, as well as academic and public research centers, and pharmaceutical and biotechnology companies, are the primary customers for outsourced NGS services, which are deployed for oncology, rare disease testing, reproductive health, infectious disease applications, and drug discovery.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Population genomics and pathogen surveillance programs creating steady service volumes
-
Falling sequencing cost and easy access to scalable capacity
Level
-
Uneven reimbursement and limited coverage for clinical sequencing
Level
-
Multi-omics service bundles for drug discovery and translational research
-
Sample-to-report' diagnostic services with interpretation and reanalysis
Level
-
hortage of specialized talent in bioinformatics and clinical interpretation
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Population genomics and pathogen surveillance programs creating steady service volumes
Many countries are funding large genomics and surveillance efforts. These programs require consistent throughput and repeated testing over extended periods. Service providers benefit because they can centralize workflows and scale quickly. This drives recurring demand for sequencing, plus analysis and reporting.
Restraint: Uneven reimbursement and limited coverage for clinical sequencing
Payment pathways still vary widely by country and payer. Hospitals may hesitate to send routine cases when reimbursement is unclear, which slows adoption in diagnostics, even when clinical value is recognized. Service volumes then grow unevenly across regions and indications.
Opportunity: Growth of multi-omics, data analytics, and biopharma collaborations
Clients are increasingly requiring the integration of genomics with transcriptomics and other omics layers. This improves target identification, biomarker work, and patient stratification. Service providers can solve bigger programs by offering one integrated workflow. Demand rises further when analysis, interpretation, and sequencing are included.
Challenge: Shortage of specialized talent in bioinformatics and clinical interpretation
Scaling services needs trained analysts, in addition to sequencing machines. Many regions face gaps in genomics data science and reporting expertise; this can hit turnaround time and create bottlenecks as volumes rise. Providers must invest in training, automation, and standardized pipelines to keep pace.
NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Scientists studying Usutu virus sent viral nucleic acid to Eurofins Genomics for a dedicated RNA-virus sequencing service (INVIEW virus sequencing) on an Illumina NovaSeq 6000 to generate whole-genome data for analysis and comparison with other methods | Quick access to high-quality viral genomes | High-throughput sequencing without adding lab capacity | Supports surveillance and phylogenetics | Clean data for downstream bioinformatics |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global next-generation sequencing services market environment comprises sequencing service providers, specialty clinical labs, and research-focused genomics partners. These entities perform high-throughput workflows for whole-genome, whole-exome, targeted panels, RNA sequencing, metagenomics, and single-cell projects. A large number of them also offer the services of sample handling, library preparation, QC, bioinformatics, and interpretation, so that customers obtain the most processed results and not just raw data. On the demand side, biopharma companies, CROs, hospitals, reference labs, academic centers, and public health agencies are the primary users. They use service providers as a means to scale their programs in oncology, rare disease testing, reproductive health, infectious disease surveillance, and drug ??????discovery.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
NGS Services Market, By Service type
As of 2024, sequencing services accounted for the largest share of the global next-generation sequencing services market and are expected to remain the leading service type over the next several years. This is driven by steady demand from clinical labs, hospitals, academic centers, and biopharmaceutical companies for scalable access to whole-genome sequencing, whole-exome sequencing, targeted panels, RNA sequencing, and metagenomics without the need to expand in-house capacity.
NGS Services Market, By Workflow
As of 2024, the sequencing step accounted for the largest share of the global next-generation sequencing services market by workflow and is expected to remain the dominant step over the next several years. This is because sequencing is the core value-creating activity that determines data yield, accuracy, turnaround time, and cost per sample. Service providers generate the majority of their workflow revenue by running high-throughput sequencing across WGS, WES, targeted panels, RNA-seq, and metagenomics for clinical and research customers.
NGS Services Market, By Application
As of 2024, the diagnostics sector was the major contributor to the global next-generation sequencing services market in terms of application and is anticipated to maintain its dominance for the following years. A key factor supporting this trend is the fact that clinical users are turning to external sequencing services more and more in order to obtain ready-to-report results without the need to set up large in-house sequencing and bioinformatics teams. The highest demand for diagnostic services is associated with oncology profiling (support for tissue and liquid biopsies), genetic and rare disease testing, reproductive health screening, as well as infectious disease identification and surveillance.
NGS Services Market, By End user
As?????? of 2024, academic & research institutes were the major contributors to the global next-generation sequencing services market by end user and are projected to remain the leading segment during the forecast period. These institutions, universities, and research centers are involved in numerous projects, including whole-genome, whole-exome, RNA-seq, metagenomics, and single-cell studies. To get high-throughput capacity and save on the costs of instruments and staff in their labs, they frequently outsource ??????sequencing.
REGION
Asia Pacific to be the fastest-growing region in the global NGS services market during the forecast period
The next-generation sequencing services market is expected to grow significantly over the forecast period, driven by the expansion of genomics and precision medicine programs across countries such as China, India, Japan, and South Korea. Growth is further propelled by rising biopharmaceutical R&D and clinical trials that rely on NGS-based biomarker discovery, together with a rapidly expanding molecular diagnostics and oncology testing ecosystem and increasing investments in automation, AI-enabled bioinformatics, and cloud-based data platforms to support high-throughput and decentralized sequencing workflows.
NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET: COMPANY EVALUATION MATRIX
In the global next-generation sequencing services matrix, Illumina (Star) is combining a technological ecosystem to capture a large share of the outsourced sequencing capacity globally, which supports its leading position. By using Illumina platforms, service providers and large reference labs carry out high-throughput whole-genome, whole-exome, targeted panel, and RNA sequencing. WuXi Biologics (Emerging Leader) is becoming more prominent on the services side as biopharma customers increasingly seek partners who can provide them with end-to-end development support, along with strong analytical capabilities. Although WuXi Biologics is not a purely sequencing lab, its expanding involvement in biologics development and manufacturing is attracting more demand for sequencing-enabled workflows linked to cell line and clone characterization, genetic stability, and translational support.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific, Inc. (US)
- Eurofins Scientific (Luxembourg)
- Wuxi Biologics (China)
- Qiagen (Netherlands)
- Revvity (US)
- BGI Group (China)
- Macrogen, Inc. (South Korea)
- Azenta US (US)
- Novogene Co. Ltd (China)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 3.40 Billion |
| Market Forecast in 2030 (Value) | USD 8.78 Billion |
| Growth Rate | CAGR of 18.2% from 2025-2030 |
| Years Considered | 2022-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
| Parent & Related Segment Reports |
Next generation Sequencing Market North America Next Generation Sequencing Market Europe Next Generation Sequencing Market Asia Pacific Next Generation Sequencing Market Germany Next Generation Sequencing Market France Next Generation Sequencing Market UK Next-generation Sequencing Market South Korea Next-Generation Sequencing Market China Next Generation Sequencing Market Single-Molecule Real Time (SMRT) Sequencing Market |
WHAT IS IN IT FOR YOU: NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Global NGS service provider / sequencing lab network | Competitive benchmarking of global NGS service providers by service menu (WGS/WES/panels/RNA-seq/metagenomics/single-cell), pricing bands, and turnaround times |
|
| Bioinformatics / software platform company |
|
|
RECENT DEVELOPMENTS
- June 2026: F. Hoffmann-La Roche Ltd. launched AXELIOS 1, a new next-generation sequencing platform powered by Roche’s proprietary Sequencing by Expansion (SBX) technology. The research-use-only system provides single-molecule sequencing with near-real-time analysis and is designed to deliver same-day whole-genome sequencing, combining speed, scalability and flexibility for genomic research.
- May 2026: Illumina, Inc. introduced a new distributed whole-genome sequencing solution for highly sensitive molecular residual disease (MRD) research, built on the NovaSeq X platform. The solution combines whole-genome sequencing with a distributed kit workflow and is designed for solid-tumor MRD and blood-cancer genomic profiling, marking the first offering in Illumina’s new WGS oncology research portfolio
- April 2026: QIAGEN introduced new QIAseq research panels for use on next-generation sequencers, including the QIAseq xHYB HRD Panel and QIAseq xHYB Trinity DNA/RNA Kit. The products expand QIAGEN’s NGS portfolio for genomic profiling, with the Trinity kit supporting comprehensive DNA/RNA profiling on the Element Biosciences AVITI platform while reducing hands-on workflow steps.
- September 2025 : Illumina announced the launch of Illumina Protein Prep, an assay designed for next-generation sequencing (NGS)-based proteomics research. The product enables integration of proteomics into large-scale genomics studies across cancer, cardiometabolic, and immunologic research.
- July 2025 : QIAGEN launched its new QIAseq xHYB Long Read Panels, a set of target enrichment tools designed to support long-read sequencing of complex genomic regions. The panels are optimized for compatibility with native long-read platforms, such as those from PacBio, and are intended to improve detection of a broader range of genomic variations.
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Germany's NGS services market grew from $111.1M (2017) to $290.7M (2022), representing a 21.2% CAGR and outpacing global growth rates.
- Germany's advanced healthcare infrastructure and biotech investment ecosystem position the country as Europe's leading NGS services market.
- Clinical adoption of NGS in Germany spans oncology, rare disease diagnosis, and pharmacogenomics, driving service demand across multiple healthcare segments.
- Germany's regulatory framework and precision medicine initiatives support sustained NGS market expansion through 2022 and beyond.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Germany Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Pharmaceutical & Biotech Companies : German and international pharma firms need market intelligence to guide R&D investments, clinical trial strategies, and precision medicine partnerships within Germany's growing NGS ecosystem.
- Healthcare Providers & Hospitals : German hospital networks and diagnostic centers require market data to justify NGS service investments, benchmark against competitors, and plan genomic medicine program expansion.
- Diagnostic Laboratory Operators : Clinical and research laboratories in Germany need market sizing and growth forecasts to evaluate service expansion opportunities, technology upgrades, and competitive positioning in the NGS market.
- Medical Device & Technology Vendors : NGS equipment manufacturers and software providers need Germany-specific market insights to identify customer segments, forecast demand, and develop localized sales and support strategies.
- Healthcare Investors & Consultants : Private equity firms, venture capitalists, and management consultants require validated market data for Germany to evaluate investment opportunities and advise clients on genomic healthcare ventures.
Key Companies in the Germany Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for Germany's NGS services sector with verified CAGR of 21.2%, enabling accurate financial forecasting and investment decision-making for market entry or expansion strategies.
- Competitive Landscape Intelligence : Understand Germany's unique market dynamics, key players, and competitive positioning within Europe's genomic services ecosystem to identify partnership opportunities and differentiation strategies.
- Regional Growth Drivers Analysis : Access detailed insights into Germany-specific factors driving NGS adoption, including healthcare infrastructure strengths, regulatory environment, and precision medicine initiatives shaping market demand.
- Strategic Market Entry Planning : Leverage comprehensive Germany market data to develop targeted go-to-market strategies, identify high-potential customer segments, and allocate resources effectively for successful market penetration.
- Investment & Funding Decisions : Support capital allocation decisions with validated market forecasts and growth projections specific to Germany, enabling confident investment in NGS service infrastructure and technology development.
Frequently asked questions
What was Germany's NGS services market size in 2017?
Germany's NGS services market was valued at $111.1 million in 2017, establishing a strong baseline for subsequent growth through 2022.
What is the projected market size for Germany's NGS services by 2022?
Germany's NGS services market is forecasted to reach $290.7 million by 2022, reflecting significant expansion driven by clinical adoption and technological advancement.
What is Germany's NGS services market CAGR?
Germany's NGS services market is projected to grow at a compound annual growth rate of 21.2% between 2017 and 2022, outpacing global averages.
Which sectors drive NGS service demand in Germany?
Germany's NGS service demand is driven by oncology diagnostics, rare disease identification, pharmacogenomics, and research institutions leveraging precision medicine approaches.
Why is Germany a key NGS services market in Europe?
Germany's leadership in the European NGS market stems from its advanced healthcare infrastructure, substantial biotech investment, regulatory support for genomic medicine, and strong pharmaceutical sector integration.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
